Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of

Name: Phase 3 Topline: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of
Start: 2028-06-01

June 1, 2028

Company: MOLECULAR PARTNERS AG (MOLN)
Drug: single
Indication: Macular Neovascularization Secondary to Age-Related Macular Degeneration

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of — MOLN Phase 3 Readout | BioSniper